Bortezomib mitigates adverse prognosis conferred by Bcl-2 overexpression in patients with relapsed/refractory multiple myeloma

Leukemia and Lymphoma

Volumn 53, Issue 6, 2012, Pages 1174-1182

  Ailawadhi, Sikander ^a   Miecznikowski, Jeff ^b   Gaile, Dan P ^b   Wang, Dongliang ^b   Sher, Taimur ^c   Mulligan, George ^d   Bryant, Barb ^d   Wilding, Gregory E ^b   Mashtare, Terry ^b   Stein, Leighton ^b   Masood, Aisha ^c   Neuwirth, Rachel ^d   Lee, Kelvin P ^c   Chanan Khan, Asher ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Bcl 2; Bortezomib; Myeloma

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; MICROARRAY ANALYSIS; MULTICENTER STUDIES AS TOPIC; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; RECURRENCE; TREATMENT FAILURE; UP-REGULATION;

EID: 84861381663     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.637212     Document Type: Article

References (48)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Cavo M, Terragna C, Renzulli M, et al. Poor outcome with frontline autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. J Clin Oncol 2006;24:e4-e5.
3. Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837-2840. (Pubitemid 41510761)
4. Jaksic W, Trudel S, Chang H, et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005;23: 7069-7073.
5. Stewart AK, Fonseca R. Prognostic and therapeutic signifi cance of myeloma genetics and gene expression profi ling. J Clin Oncol 2005; 23:6339-6344. (Pubitemid 46218844)
6. Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profi ling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007;109:3177-3188. (Pubitemid 46572502)
7. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007;67:5418-5424. (Pubitemid 46997282)
8. Spets H, Stromberg T, Georgii-Hemming P, et al. Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6 (IL-6)-induced growth and survival. Eur J Haematol 2002;69:76-89. (Pubitemid 35178106)
9. van de Donk NW, Bloem AC, van der Spek E, et al. New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway. Curr Pharm Des 2006;12:327-340.
10. van de Donk NW, Kamphuis MM, van Dijk M, et al. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein. Leukemia 2003;17:211-219. (Pubitemid 36175908)
11. Wang HG, Reed JC. Mechanisms of Bcl-2 protein function. Histol Histopathol 1998;13:521-530.
12. Baliga BC, Kumar S. Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 2002;20:63-74. (Pubitemid 34654300)
13. Pepper C, Th omas A, Hidalgo de Quintana J, et al. Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia-the role of Bcl-2 family dysregulation. Leuk Res 1999;23:1007-1014. (Pubitemid 29488647)
14. Tu Y, Renner S, Xu F, et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res 1998;58:256-262. (Pubitemid 28047064)
15. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442.
16. Wuilleme-Toumi S, Robillard N, Gomez P, et al. Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005;19:1248-1252. (Pubitemid 40946011)
17. Li M, Chen F, Clifton N, et al. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma Effect. Mol Cancer Ther 2010;9:3200-3209.
18. Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003;17:2036-2045. (Pubitemid 37322135)
19. Pei XY, Dai Y, Grant S. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with fl avopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radicaldependent and Jun NH2-terminal kinase-dependent mechanism. Mol Cancer Ther 2004;3:1513-1524. (Pubitemid 40136706)
20. Trudel S, Stewart AK, Li Z, et al. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic Effect with dexamethasone and melphalan. Clin Cancer Res 2007;13:621-629. (Pubitemid 46225369)
21. Chanan-Khan AA, Niesvizky R, Hohl RJ, et al. Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma. Leuk Lymphoma 2009; 50:559-565.
22. Badros AZ, Goloubeva O, Rapoport AP, et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 2005;23:4089-4099. (Pubitemid 46211314)
23. van de Donk NW, de Weerdt O, Veth G, et al. G3139, a Bcl-2 antisense oligodeoxynucleotide, induces clinical responses in VAD refractory myeloma. Leukemia 2004;18:1078-1084. (Pubitemid 38786966)
24. Chang H, Trieu Y, Qi X, et al. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leuk Res 2007;31:779-782. (Pubitemid 46855891)
25. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007;21:151-157. (Pubitemid 44921846)
26. Sagaster V, Ludwig H, Kaufmann H, et al. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007;21: 164-168. (Pubitemid 44921848)
27. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-172. (Pubitemid 39371809)
28. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617. (Pubitemid 36741588)
29. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498. (Pubitemid 41007864)
30. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123. (Pubitemid 28435189)
31. Hoaglin DC, Mosteller F, Tukey JW. Understanding robust and exploratory data analysis. New York: John Wiley Sons; 2000.
32. Hashmi M, Kojouri K, Yang J, et al. Prognostic signifi cance of BCL-2 expression in patients with multiple myeloma. Blood 2004;104 (Suppl. 1): Abstract 4840.
33. Largo C, Alvarez S, Saez B, et al. Identifi cation of overexpressed genes in frequently gained/amplifi ed chromosome regions in multiple myeloma. Haematologica 2006;91:184-191.
34. Wellek S. Testing statistical hypotheses of equivalence. Boca Raton, FL: Chapman Hall/CRC; 2003.
35. Hintze JL, Nelson RD. Violin plots: a box plot-density trace synergism. Am Stat 1998;52:181-184.
36. Ambroise C, McLachlan GJ. Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci USA 2002;99:6562-6566. (Pubitemid 34526172)
37. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2004;2:E108.
38. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifi ers. J Clin Oncol 2005;23:7332-7341. (Pubitemid 46202346)
39. Puthier D, Pellat-Deceunynck C, Barille S, et al. Differential expression of Bcl-2 in human plasma cell disorders according to proliferation status and malignancy. Leukemia 1999;13: 289-294. (Pubitemid 29092663)
40. Sangfelt O, Osterborg A, Grander D, et al. Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein. Int J Cancer 1995;63:190-192.
41. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-8607. (Pubitemid 38028528)
42. Harada N, Hata H, Yoshida M, et al. Expression of Bcl-2 family of proteins in fresh myeloma cells. Leukemia 1998;12:1817-1820. (Pubitemid 28502503)
43. Kline MP, Rajkumar SV, Timm MM, et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007;21:1549-1560. (Pubitemid 46965297)
44. Kline MP, Rajkumar SV, Timm MM, et al. R-(-)-gossypol (AT-101) activates programmed cell death in multiple myeloma cells. Exp Hematol 2008;36:568-576.
45. Chauhan D, Velankar M, Brahmandam M, et al. A novel Bcl-2/ Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007;26:2374-2380. (Pubitemid 46572819)
46. Winter JN, Weller EA, Horning SJ, et al. Prognostic signifi cance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006;107:4207-4213. (Pubitemid 43801342)
47. Chanan-Khan AA, Kaufman JL, Mehta J, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109: 2604-2606. (Pubitemid 46425908)
48. Richardson PG, Barlogie B, Berenson J, et al. Extended followup of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006;106: 1316-1319. (Pubitemid 43363908)